Dr. Petrylak on Atezolizumab in Bladder Cancer
Daniel Petrylak, MD, on investigating atezolizumab and cabozantinib relating to prostate cancerПодробнее
Dr. Daniel Petrylak on the IMvigor Study of Atezolizumab in Advanced Bladder CancerПодробнее
Dr. Petrylak on Trial of Atezolizumab in Urothelial CarcinomaПодробнее
Dr. Petrylak on FDA Approval of Nivolumab in Bladder CancerПодробнее
Dr. Petrylak on Novel Immunotherapy Research in Bladder CancerПодробнее
Dr. Petrylak on FDA Approval of Pembrolizumab in Bladder CancerПодробнее
Dr. Petrylak on the Future Immunotherapy in Bladder CancerПодробнее
FDA Approval of Atezolizumab for Advanced Bladder CancerПодробнее
Dr. Petrylak on Immunotherapy in Bladder CancerПодробнее
Dr. Petrylak on Immunotherapy for Second-line Treatment in Bladder CancerПодробнее
Dr. Petrylak on the Results of the EV-103 Trial in Bladder CancerПодробнее
Dr Daniel Petrylak Explains PD-1, PD-L1 Expression in Bladder Cancer TreatmentПодробнее
ASCO GU 2020: Dr. Petrylak Discusses Exciting Prostate Cancer and Bladder Cancer DataПодробнее
Dr. Daniel Petrylak on Early Trials for a New Urothelial Bladder Cancer TreatmentПодробнее
Meet Oncologist Daniel Petrylak, MDПодробнее
Dr. David Nanus on Atezolizumab for Urothelial Bladder CancerПодробнее
Dr. Petrylak on Sequencing of Targeted Agents in Bladder CancerПодробнее
Dr. Petrylak on Ongoing Investigations of Checkpoint Inhibition in Bladder CancerПодробнее
FDA approves new bladder cancer drug | Dr. Daniel PetrylakПодробнее
